Cargando…

Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis

PURPOSE: Evidence suggests that neurotrophic tyrosine receptor kinase (NTRK) gene fusions in solid tumors are predictive biomarkers for targeted inhibition across a number of adult and pediatric tumor types. However, despite robust clinical response to tyrosine receptor kinase (TRK) inhibitors, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lassen, Ulrik, Bokemeyer, Carsten, Garcia-Foncillas, Jesus, Italiano, Antoine, Vassal, Gilles, Paracha, Noman, Marian, Marisca, Chen, Yuxian, Linsell, Louise, Abrams, Keith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	REVIEW ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581655/ https://www.ncbi.nlm.nih.gov/pubmed/37384865 http://dx.doi.org/10.1200/PO.22.00651

Ejemplares similares

Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data
por: Bokemeyer, Carsten, et al.
Publicado: (2023)

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
por: Garcia-Foncillas, Jesus, et al.
Publicado: (2022)

Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion–Positive Solid Tumors
por: Bokemeyer, Carsten, et al.
Publicado: (2021)

Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
por: Stenzinger, Albrecht, et al.
Publicado: (2023)

Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis
por: Italiano, Antoine, et al.
Publicado: (2020)

A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors
por: Forsythe, Anna, et al.
Publicado: (2020)

How I treat NTRK gene fusion-positive cancers
por: Lassen, Ulrik
Publicado: (2019)

The First Reported Case of Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Thymoma Treated Successfully With Entrectinib
por: Salame, Hassan, et al.
Publicado: (2021)

Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients
por: Viller Tuxen, Ida, et al.
Publicado: (2019)

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
por: Yang, James C. H., et al.
Publicado: (2022)

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
por: Enrico, Diego, et al.
Publicado: (2020)

Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas
por: Stravodimou, Athina, et al.
Publicado: (2022)

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
por: Peyraud, Florent, et al.
Publicado: (2020)

The Neurotrophic Receptor Tyrosine Kinase in MEC-mPFC Neurons Contributes to Remote Memory Consolidation
por: Hong, Jongryul, et al.
Publicado: (2022)

Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients
por: Paracha, Noman, et al.
Publicado: (2018)

Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature
por: Pattwell, Siobhan S., et al.
Publicado: (2020)

The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform
por: Mohamed, Fawaz, et al.
Publicado: (2022)

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours
por: Bono, Petri, et al.
Publicado: (2020)

Mixture Cure Models in Oncology: A Tutorial and Practical Guidance
por: Felizzi, Federico, et al.
Publicado: (2021)

Expression of Brain-derived Neurotrophic Factor and Tyrosine Kinase B in Cerebellum of Poststroke Depression Rat Model
por: Li, Yun, et al.
Publicado: (2015)

Brain-Derived Neurotrophic Factor Dysregulation as an Essential Pathological Feature in Huntington’s Disease: Mechanisms and Potential Therapeutics
por: Speidell, Andrew, et al.
Publicado: (2023)

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
por: Hennigs, Jan K, et al.
Publicado: (2011)

Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
por: Gorgulho, Joao, et al.
Publicado: (2023)

Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)
por: Paracha, Noman, et al.
Publicado: (2022)

Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers
por: Sutherland, C. Simone, et al.
Publicado: (2021)

Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management
por: Paracha, Noman, et al.
Publicado: (2021)

Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)
por: Paracha, Noman, et al.
Publicado: (2021)

The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung
por: Gao, Fangfang, et al.
Publicado: (2018)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphoma
por: Ghandili, Susanne, et al.
Publicado: (2023)

Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma
por: Stüben, Björn-Ole, et al.
Publicado: (2022)

Neurotrophic tyrosine kinase receptor 1 is a direct transcriptional and epigenetic target of IL-13 involved in allergic inflammation
por: Rochman, M., et al.
Publicado: (2014)

Neurogenin 3 is regulated by neurotrophic tyrosine kinase receptor type 2 (TRKB) signaling in the adult human exocrine pancreas
por: Shamblott, Michael J., et al.
Publicado: (2016)

Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer
por: Ge, Li, et al.
Publicado: (2017)

The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements
por: Delgado, J., et al.
Publicado: (2021)

Role of Mesencephalic Astrocyte-Derived Neurotrophic Factor in Alcohol-Induced Liver Injury
por: Chhetri, Goma, et al.
Publicado: (2020)

Brain-derived and glial cell line-derived neurotrophic factor fusion protein immobilization to laminin
por: Wang, Baoxin, et al.
Publicado: (2017)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
por: Zhang, Shannon S., et al.
Publicado: (2022)

Thalidomide and neurotrophism
por: Soper, Judith R., et al.
Publicado: (2018)

Upregulation of mesencephalic astrocyte-derived neurotrophic factor in glial cells is associated with ischemia-induced glial activation
por: Shen, Yujun, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qt3v3uea6hmucdkhoaf9k1tmuh